Earnings ·
Context Therapeutics reports Q3 net loss of $7.6M, cash of $34.4M
CNTXContext Therapeutics Inc.
Context Therapeutics Inc. reported a third quarter 2026 net loss of $7.6 million, compared to a $9.7 million loss in the prior-year period. Research and development expenses decreased to $5.7 million from $8.7 million, primarily due to lower costs for its CT-202 program. The company held cash and cash equivalents of $34.4 million as of September 30, 2026, which it expects will fund operations into early Q4 2027. Clinically, the firm provided updates on its CTIM-76 program in platinum-resistant ovarian cancer, noting a confirmed objective response rate of 22% and median progression-free survival of 5.6 months at weekly doses of 140–280 µg. Dose escalation to 420 µg every three weeks is ongoing, with Phase 1b initiation expected in Q1 2027. Context Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors.